Page 62 - AN-3-3

Advanced Neurology HS-proteoglycans and brain function

45. Kurz C, Walker L, Rauchmann BS, Perneczky R. doi: 10.1073/pnas.2009931117
Dysfunction of the blood-brain barrier in Alzheimer’s 56. Zhang Q, Ma C, Chin LS, Li L. Integrative glycoproteomics
disease: Evidence from human studies. Neuropathol Appl reveals protein N-glycosylation aberrations and
Neurobiol. 2022;48:e12782.
glycoproteomic network alterations in Alzheimer’s disease.
doi: 10.1111/nan.12782 Sci Adv. 2020;6(40):eabc5802.
46. Saitoh M, Takayama K, Hitachi K, et al. Discovery of a doi: 10.1126/sciadv.abc5802
follistatin-derived myostatin inhibitory peptide. Bioorg Med 57. Castillo GM, Lukito W, Wight TN, Snow AD. The sulfate
Chem Lett. 2020;30(3):126892. moieties of glycosaminoglycans are critical for the
doi: 10.1016/j.bmcl.2019.126892 enhancement of beta-amyloid protein fibril formation.
J Neurochem. 1999;72(4):1681-1687.
47. Stetefeld J, Jenny M, Schulthess T, et al. The laminin-binding
domain of agrin is structurally related to N-TIMP-1. Nat doi: 10.1046/j.1471-4159.1999.721681.x
Struct Biol. 2001;8(8):705-709. 58. Parham C, Auckland L, Rachwal J, Clarke D, Bix G. Perlecan
doi: 10.1038/90422 domain V inhibits amyloid-β induced brain endothelial cell
toxicity and restores angiogenic function. J Alzheimers Dis.
48. Song L, Oseid DE, Wells EA, Coaston T, Robinson AS. 2014;38(2):415-423.
Heparan sulfate proteoglycans (HSPGs) serve as the
mediator between monomeric tau and its subsequent doi: 10.3233/JAD-130683
intracellular ERK1/2 pathway activation. J Mol Neurosci. 59. Parham CL, Shaw C, Auckland LD, Dickeson SK, Griswold-
2022;72(4):772-791. Prenner I, Bix G. Perlecan domain V inhibits amyloid-β
doi: 10.1007/s12031-021-01943-2 induced activation of the α2β1 integrin-mediated neurotoxic
signaling cascade. J Alzheimers Dis. 2016;54(4):1629-1647.
49. Rauch J, Chen JJ, Sorum AW, et al. Tau internalization is
regulated by 6-O sulfation on heparan sulfate proteoglycans doi: 10.3233/JAD-160290
(HSPGs). Sci Rep. 2018;8(1):6382. 60. Trout A, Kahle MP, Roberts JM, et al. Perlecan domain-V
doi: 10.1038/s41598-018-24904-z enhances neurogenic brain repair after stroke in mice. Transl
Stroke Res. 2021;12(1):72-86.
50. Sikorska B, Liberski PP. Human prion diseases: From kuru
to variant Creutzfeldt-Jakob disease. Subcell Biochem. doi: 10.1007/s12975-020-00800-5
2012;65:457-496. 61. Lee B, Clarke D, Al Ahmad A, et al. Perlecan domain V is
doi: 10.1007/978-94-007-5416-4_17 neuroprotective and proangiogenic following ischemic
stroke in rodents. J Clin Invest. 2011;121(8):3005-3023.
51. Hara H, Chida J, Uchiyama K, et al. Neurotropic influenza A
virus infection causes prion protein misfolding into infectious doi: 10.1172/JCI46358
prions in neuroblastoma cells. Sci Rep. 2021;11(1):10109. 62. Lorente-Gea, L, Garcia B, Martin C, et al. Heparan sulfate
doi: 10.1038/s41598-021-89586-6 proteoglycans undergo differential expression alterations
in Alzheimer disease brains. J Neuropathol Exp Neurol.
52. Lukiw W, Jaber VR, Pogue AI, Zhao Y. SARS-CoV-2 invasion 2020;79(5):474-483.
and pathological links to prion disease. Biomolecules.
2022;12(9):1253. doi: 10.1093/jnen/nlaa016
doi: 10.3390/biom12091253 63. Doan R, Bae BI, Cubelos B, et al. Mutations in human
accelerated regions disrupt cognition and social behavior.
53. Yamashita S, Kamatari YO, Honda R, et al. Monomeric Cell. 2016;167(2):341-354.e12.
a-synuclein (aS) inhibits amyloidogenesis of human prion
protein (hPrP) by forming a stable aS-hPrP hetero-dimer. doi: 10.1016/j.cell.2016.08.071
Prion. 2021;15(1):37-43. 64. Letoha T, Hudak A, Kusz E, et al. Contribution of syndecans
doi: 10.1080/19336896.2021.1910176 to cellular internalization and fibrillation of amyloid-β(1-42).
Sci Rep. 2019;9(1):1393.
54. Wakhloo D, Oberhauser J, Madira A, Mahajani S. From
cradle to grave: Neurogenesis, neuroregeneration and doi: 10.1038/s41598-018-37476-9
neurodegeneration in Alzheimer’s and Parkinson’s diseases. 65. Lauri SE, Kaukinen S, Kinnunen T, et al. Regulatory role
Neural Regen Res. 2022;17:2606-2614. and molecular interactions of a cell-surface heparan sulfate
proteoglycan (N-syndecan) in hippocampal long-term
doi: 10.4103/1673-5374.336138
potentiation. J Neurosci. 1999;19(4):1226-1235.
55. Iwahashi N, Ikezaki M, Nishikawa T, et al. Sulfated
glycosaminoglycans mediate prion-like behavior of p53 doi: 10.1523/JNEUROSCI.19-04-01226.1999
aggregates. Proc Natl Acad Sci U S A. 2020;117(52):33225-33234. 66. Kranenburg O, Kroon-Batenburg LM, Reijerkerk A, Wu YP,

Volume 3 Issue 3 (2024) 15 doi: 10.36922/an.3812